AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Compass Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00LPXKF34
0.76▼ 0.04 (-5.05%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
0.80
Day's Range
0.75 – 0.81
52-Week Range
0.75 – 6.95
Volume
2.1M
Avg Volume
5.7M
Share Statistics
Shares Outstanding
Employees
39
Exchange
XNAS
Listed
2020-11-13
Share count as of July 28, 2026

Compass Therapeutics, Inc. Common Stock (CMPX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Compass Therapeutics, Inc. Common Stock (CMPX)
What is Compass Therapeutics, Inc. Common Stock's Market Cap?
Compass Therapeutics, Inc. Common Stock's Market Cap is $137.0M, based on as-reported figures from SEC (XBRL) filings.
What is Compass Therapeutics, Inc. Common Stock's Revenue (TTM)?
Compass Therapeutics, Inc. Common Stock's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Compass Therapeutics, Inc. Common Stock's Net Income (TTM)?
Compass Therapeutics, Inc. Common Stock's Net Income (TTM) is -$73.4M, based on as-reported figures from SEC (XBRL) filings.
What is Compass Therapeutics, Inc. Common Stock's EBITDA?
Compass Therapeutics, Inc. Common Stock's EBITDA is -$81.0M, based on as-reported figures from SEC (XBRL) filings.
What is Compass Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Compass Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.41, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CMPXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development—
General and administrative—
Total operating expenses—
Loss from operations—
Interest income—
Net loss
Net loss per share - basic and diluted (in dollars per share)—